Needham analyst Ami Fadia raised the firm’s price target on Praxis Precision (PRAX) to $460 from $315 and keeps a Buy rating on the shares. The firm sees 2026 as an extension of 2025 for the stock, with multiple new drug application submissions. Praxis could also win approval for ulixacaltamide in essential tremor, if given priority review, based on the unmet need, the analyst tells investors in a research note. Needham sees positive momentum for Praxis in 2026 based on potential approval and multiple data catalysts.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- 3 ‘Strong Buy’ Stocks to Buy Today, 12/31/2025, According to Top Analysts
- Praxis Precision falls -5.7%
- Compelling Risk‑Reward in Praxis Precision Medicines: Breakthrough Ulixacaltamide, Platform Upside, and $340 Target Price Support Buy Rating
- Praxis Precision rises 14.1%
- Praxis Precision Medicines: Breakthrough Neurology Pipeline and Regulatory Momentum Support Upside and Buy Rating